REG - Oncimmune Hldgs PLC - Appointment of Administrators & Nomad Resignation

Oncimmune HoldingsAnnouncement

26/03/2025 13:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250326:nRSZ3441Ca&default-theme=true

RNS Number : 3441C  Oncimmune Holdings PLC  26 March 2025

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company", together with its subsidiary "the Group")

 

Appointment of Administrators

and

Resignation of Nominated Adviser and Joint Brokers

 

Oncimmune Holdings plc (AIM: ONC.L) today announces that, further to its
announcement on 17 March 2025,  IPF Invest Co 2 S.A.R.L. ("IPF") has
appointed Simon Bonney and James Varney of Arafino Advisory Limited as its
joint administrators.

As a result of IPF's appointment of administrators, Cavendish Capital Markets
Limited has informed the Company of its resignation as Nominated Adviser and
Joint Broker to the Company with immediate effect.  Pursuant to AIM Rule 1,
if a replacement Nominated Adviser is not appointed within one month from the
resignation of the current Nominated Adviser, the admission of the Company's
shares to trading on AIM will be cancelled. The Company has no current
intention of appointing a replacement Nominated Adviser. Furthermore, the
Company announces the resignation of Zeus Capital Limited as Joint Broker with
immediate effect.

Any party interested in acquiring any assets of the Group should contact the
joint administrators as soon as possible by email at ONC@arafino.com.

 

For further information:

 

contact@oncimmune.com (mailto:contact@oncimmune.com)

ONC@arafino.com

 

 

About Oncimmune

 

Oncimmune is a precision medicine company, specialising in analysing immune
interactions through the autoantibody profile. Taking a platform approach to
generating insights, Oncimmune is partnering with global pharmaceutical and
biotech companies, as well as contract research organisations (CROs) to
discover novel biomarkers for the development of more targeted and effective
therapies across many immune-mediated diseases. Our mission at Oncimmune is to
enable precision medicine. We help our partners to discover novel biomarkers,
drug targets and predict treatment efficacy through the application of our
platform. We are able to do this by deploying our world class scientific team
and our cutting-edge technology platform, built on years of experience in the
field. Our aim is to make this an essential tool in drug discovery and
development.

Oncimmune is headquartered in the UK, with its discovery and development
facility based in Dortmund, Germany and a business development team based in
the US and Europe.

 

For more information, visit www.oncimmune.com (http://www.oncimmune.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPPPUGCWUPAGPQ